Profil bibliographique

Hani Kushlaf

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

79Publications signalées

847Citations signalées

3Affiliations récentes

Institutions déclarées

Cincinnati Children's Hospital Medical Center University of Cincinnati University of Cincinnati Medical Center

Domaines associés

Lysosomal Storage Disorders ResearchGlycogen Storage Diseases and MyoclonusGenetic Neurodegenerative DiseasesMyasthenia Gravis and ThymomaParkinson's Disease and Spinal Disorders

Publications récentes

Accès ouvert 2025 articleOpenAlex

Elevated Levels of Active GSK3β in the Blood of Patients with Myotonic Dystrophy Type 1 Correlate with Muscle Weakness

Katherine M. Jennings, Cuixia Tian, Rebeccah L. Brown, Paul S. Horn et autres

2 citationsInternational Journal of Molecular Sciences

2025 articleOpenAlex

Muscle Channelopathies and Rhabdomyolysis

Hani Kushlaf

1 citationCONTINUUM Lifelong Learning in Neurology

2025 articleOpenAlex

69PClinically important improvements in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat

Kristl G. Claeys, Hani Kushlaf, Stephan Wenninger, N Hummel et autres

0 citationsNeuromuscular Disorders

Accès ouvert 2025 articleOpenAlex

Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial

Priya S. Kishnani, Jordi Díaz‐Manera, С. Н. Иллариошкин, Ans T. van der Ploeg et autres

9 citationsJournal of Neurology

2025 articleOpenAlex

Lymphocyte Activation Gene 3 in Inclusion Body Myositis: A Novel Therapeutic Biomarker?

Hani Kushlaf

0 citationsMuscle & Nerve

Accès ouvert 2025 articleOpenAlex

Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy

Marianela Schiava, Yolande Parkhurst, Matthew Henderson, Tuomo Polvikoski et autres

2 citationsNeurology Genetics

Accès ouvert 2025 articleOpenAlex

Switching Enzyme Replacement Therapy for Late‐Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL

Hani Kushlaf, Jordi Díaz‐Manera, Drago Bratkovic, Barry J. Byrne et autres

6 citationsMuscle & Nerve

Accès ouvert 2025 articleOpenAlex

Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review

Roberto Giugliani, Hani Kushlaf, Erica Wright, Tmirah Haselkorn et autres

6 citationsOrphanet Journal of Rare Diseases

2025 conference-paperOpenAlex

Klinisch relevante Verbesserungen der 6-Minuten-Gehstrecke (6MWD) und forcierten Vitalkapazität (FVC) bei Erwachsenen mit Morbus Pompe der späten Verlaufsform (LOPD), die in der PROPEL Studie von Alglucosidase alfa (Alg) auf Cipaglucosidase alfa plus Miglustat (Cipa+Mig) umgestellt wurden

Stephan Wenninger, Hani Kushlaf, Benedikt Schoser, N Hummel et autres

0 citationsNervenheilkunde

2025 articleOpenAlex

RNA Sequencing Confirms the Pathogenicity of a Novel FHL1 Deletion in a Kinship With Emery–Dreifuss Muscular Dystrophy

Chinmayee B. Nagaraj, Cuixia Tian, Hani Kushlaf

1 citationJournal of Clinical Neuromuscular Disease

2025 articleOpenAlex

Clinically important improvements in 6-min walk distance (6MWD) and forced vital capacity (FVC) in adults with late-onset Pompe disease (LOPD) switching from alglucosidase alfa (alg) to cipaglucosidase alfa plus miglustat (cipa + mig) in the PROPEL study

Benedikt Schoser, Hani Kushlaf, Stephan Wenninger, Noemi Hummel et autres

0 citationsMolecular Genetics and Metabolism

2024 articleOpenAlex

Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders

Hani Kushlaf

2 citationsSeminars in Respiratory and Critical Care Medicine

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.